Presbyopia-correcting IOLs evaluated in study
October 12th 2011Results of a prospective, randomized, patient-masked clinical trial evaluating three presbyopia-correcting IOLs show predictable refractive outcomes were achieved with all three technologies, but indicate there are some differences between the IOLs in visual performance, said Robert E.T. Ang, MD, Asian Eye Institute, Makati City, Philippines.
Uveitis drug earns EU orphan status
September 14th 2011The European Commission (EC) has granted orphan drug status for an immunosuppressant drug (Sirolimus, Santen Inc.) for the treatment of chronic non?infectious uveitis. The designation follows a positive opinion from the Committee for Orphan Medicinal Products within the European Medicines Agency in June.
Implantable telescope gets CMS code
September 14th 2011The Centers for Medicare and Medicaid Services (CMS) has granted transitional pass-through payment status and established a billing code for a telescope implant (Implantable Miniature Telescope [IMT] by Dr. Isaac Lipshitz, VisionCare Ophthalmic Technologies, Inc.) under the Hospital Outpatient Prospective Payment System. The new pass-through code, C1840, is effective October 1. It will enable outpatient facilities to obtain reimbursement for the telescope implant for covered procedures.
Testing benefits of conjunctivitis test
September 7th 2011Researchers hope that a clinical trial of a rapid, point-of-care test (RPS Adeno Detector Plus, Rapid Pathogen Screening Inc.), cleared by the FDA earlier this year for the diagnosis of adenoviral conjunctivitis, will help determine whether the test can help cut health care costs and reduce the number of incorrect diagnoses.
Cataract surgery cost-effective
September 7th 2011Contrary to claims made in a recent op-ed piece in the Wall Street Journal, cataract surgery ?is one of the most cost-effective major surgical procedures available today,? said American Academy of Ophthalmology (AAO) President Richard L. Abbott, MD, in an open letter.
Canadian MDL granted for dry eye test
August 31st 2011The maker of an in-office test (InflammaDry Detector, Rapid Pathogen Screening) to detect elevated levels of matrix metalloproteinase-9 (MMP?9) in tear fluid expects to begin marketing it in Canada soon now that the company has been granted a medical device license from Health Canada. The product was also recently released in Europe and Asia.
FDA extends aflibercept review
August 24th 2011The FDA has extended by 3 months its target date to complete a priority review of the biologics license application (BLA) of aflibercept injection for intravitreal use (Eylea, also known as VEGF Trap-Eye, Regeneron Pharmaceuticals) for the treatment of neovascular age-related macular degeneration (AMD) to Nov. 18.